Halozyme Therapeutics (HALO) - Stock & Dividends

Exchange: USA Stocks • Country: United States • Currency: USD • Type: Common Stock • ISIN: US40637H1095

Enzymes, Devices, Injectables, Biologics

Halozyme Therapeutics, Inc. is a biopharma technology platform company that develops and commercializes innovative enzymes and devices to improve the delivery of injectable biologics and other therapeutic molecules.

The company's products are built around its patented recombinant human hyaluronidase enzyme (rHuPH20), which enables the delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. This technology has the potential to improve the treatment of various diseases and conditions.

Halozyme's product portfolio includes Hylenex recombinant, a formulation of rHuPH20 that facilitates subcutaneous fluid administration, enhancing the dispersion and absorption of other injected drugs. The company also offers a range of products for the treatment of various diseases, including HIV, multiple sclerosis, breast cancer, and primary immunodeficiency disorders.

In addition, Halozyme provides products for the treatment of chronic lymphocytic leukemia, amyloidosis, smoldering myeloma, and multiple myeloma. The company's products also include Epinephrine Injection for the treatment of allergic reactions, as well as various other therapies for solid tumors, multifocal motor neuropathy, and autoimmune diseases.

Founded in 1998, Halozyme Therapeutics, Inc. is headquartered in San Diego, California, and has operations in the United States, Switzerland, Belgium, Japan, and internationally. The company's mission is to develop and commercialize innovative products that improve patient outcomes and quality of life.

Halozyme's commitment to innovation and patient care has led to the development of a robust pipeline of products, including ATRS-1902, a proprietary drug-device combination product, and ARGX-117, a treatment for multifocal motor neuropathy. The company's focus on research and development has enabled it to stay at the forefront of the biopharma industry.

With a strong track record of innovation and a commitment to improving patient outcomes, Halozyme Therapeutics, Inc. is a leader in the biopharma industry, dedicated to making a positive impact on the lives of patients around the world.

Drawdown (Underwater) Chart

Drawdown / Underwater Chart for Halozyme Therapeutics (HALO) - Stock & Dividends

Overall Trend and Yearly Seasonality

Drawdown / Underwater Chart for Halozyme Therapeutics (HALO) - Stock & Dividends

HALO Stock Overview

Market Cap in USD 5,690m
Sector Healthcare
Industry Biotechnology
GiC SubIndustry Biotechnology
TER 0.00%
IPO / Inception 2004-03-16

HALO Stock Ratings

Growth 5y 52.8
Fundamental 85.0
Dividend -
Rel. Performance vs Sector 3.46
Analysts 4.00/5
Fair Price Momentum 49.37 USD
Fair Price DCF 91.22 USD

HALO Dividends

Yield 12m 0.00%
Yield on Cost 5y 0.00%
Dividends CAGR 5y 0.00%
Payout Consistency 0.0%

HALO Growth Ratios

Growth 12m 41.51%
Growth Correlation 12m 13%
Growth Correlation 3m 47%
CAGR 5y 25.00%
CAGR/Mean DD 5y 1.37
Sharpe Ratio 12m 0.97
Alpha vs SP500 12m 18.83
Beta vs SP500 5y weekly 0.89
ValueRay RSI 82.49
Volatility GJR Garch 1y 37.00%
Price / SMA 50 15.74%
Price / SMA 200 26.34%
Current Volume 1418k
Average Volume 20d 1343.1k

External Links for HALO Stock

Wall Street JournalBenzingaYahoo Finance
Fund Manager Positions
What is the price of HALO stocks?
As of June 15, 2024, the stock is trading at USD 49.50 with a total of 1,418,017 shares traded.
Over the past week, the price has changed by -2.65%, over one month by +12.96%, over three months by +21.35% and over the past year by +50.14%.
What are the forecast for HALO stock price target?
According to ValueRays Forecast Model, HALO Halozyme Therapeutics will be worth about 54.1 in June 2025. The stock is currently trading at 49.50. This means that the stock has a potential upside of +9.31%.
Issuer Forecast Upside
Wallstreet Target Price 51.8 4.61
Analysts Target Price 51.9 4.85
ValueRay Target Price 54.1 9.31